Active Ingredient: Niraparib
Niraparib is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral, 300 milligrams niraparib, once daily.
The dose is 300 mg once daily.
Patients should be encouraged to take their dose at approximately the same time each day. Bedtime administration may be a potential method for managing nausea.
It is recommended that treatment should be continued until disease progression.
If patients miss a dose, they should take their next dose at its regularly scheduled time.
No dose adjustment is necessary for elderly patients (≥65 years). There are limited clinical data in patients aged 75 or over.
Niraparib can be taken without regard to meals.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
